Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RELATLIMAB for Glioblastoma multiforme: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 8 adverse event reports in the FDA FAERS database where RELATLIMAB was used for Glioblastoma multiforme.

Most Reported Side Effects for RELATLIMAB

Side Effect Reports % Deaths Hosp.
Pneumonia 13 7.3% 7 9
Malignant neoplasm progression 9 5.1% 7 7
Myocarditis 8 4.5% 1 6
Hypotension 7 4.0% 0 7
Meningitis aseptic 7 4.0% 0 7
Pyrexia 7 4.0% 0 6
Sepsis 7 4.0% 4 5
Adrenal insufficiency 6 3.4% 0 6
Drug ineffective 6 3.4% 0 2
Hepatitis 6 3.4% 1 5
Myositis 6 3.4% 1 5
Pericardial effusion 6 3.4% 0 6
Dyspnoea 5 2.8% 1 5
Headache 5 2.8% 0 3
Hyponatraemia 5 2.8% 0 5

Other Indications for RELATLIMAB

Malignant melanoma (69) Non-small cell lung cancer (26) Acute myeloid leukaemia (11) Chordoma (8) Head and neck cancer (6) Metastatic malignant melanoma (6)

Other Drugs Used for Glioblastoma multiforme

TEMOZOLOMIDE (868) BEVACIZUMAB (508) NIVOLUMAB (142) IRINOTECAN (91) DEXAMETHASONE (57) CARBOPLATIN (47) IPILIMUMAB (39) AVASTIN (36) PEMBROLIZUMAB (36) VINCRISTINE (36)

Related Pages

RELATLIMAB Full Profile All Glioblastoma multiforme Drugs RELATLIMAB Demographics RELATLIMAB Timeline